152 related articles for article (PubMed ID: 15183742)
21. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss.
Griffin CA; Burger P; Morsberger L; Yonescu R; Swierczynski S; Weingart JD; Murphy KM
J Neuropathol Exp Neurol; 2006 Oct; 65(10):988-94. PubMed ID: 17021403
[TBL] [Abstract][Full Text] [Related]
22. Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.
Gupta M; Djalilvand A; Brat DJ
Am J Clin Pathol; 2005 Nov; 124(5):755-68. PubMed ID: 16203285
[TBL] [Abstract][Full Text] [Related]
23. The expression of cell cycle regulatory proteins in oligodendroglial tumors.
Kamiya M; Nakazato Y
Clin Neuropathol; 2002; 21(2):52-65. PubMed ID: 12005253
[TBL] [Abstract][Full Text] [Related]
24. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
Sahm F; Koelsche C; Meyer J; Pusch S; Lindenberg K; Mueller W; Herold-Mende C; von Deimling A; Hartmann C
Acta Neuropathol; 2012 Jun; 123(6):853-60. PubMed ID: 22588899
[TBL] [Abstract][Full Text] [Related]
25. Is the 1p/19q deletion a diagnostic marker of oligodendrogliomas?
Gadji M; Fortin D; Tsanaclis AM; Drouin R
Cancer Genet Cytogenet; 2009 Oct; 194(1):12-22. PubMed ID: 19737649
[TBL] [Abstract][Full Text] [Related]
26. Genomic aberrations in diffuse low-grade gliomas.
Dahlback HS; Gorunova L; Brandal P; Scheie D; Helseth E; Meling TR; Heim S
Genes Chromosomes Cancer; 2011 Jun; 50(6):409-20. PubMed ID: 21412929
[TBL] [Abstract][Full Text] [Related]
27. Oligodendrogliomas: molecular biology and treatment.
Bromberg JE; van den Bent MJ
Oncologist; 2009 Feb; 14(2):155-63. PubMed ID: 19182242
[TBL] [Abstract][Full Text] [Related]
28. Comparative genomic hybridization pattern of non-anaplastic and anaplastic oligodendrogliomas--a meta-analysis.
Koschny R; Holland H; Koschny T; Vitzthum HE
Pathol Res Pract; 2006; 202(1):23-30. PubMed ID: 16356658
[TBL] [Abstract][Full Text] [Related]
29. Losses of chromosomes 1p and 19q are rare in pediatric oligodendrogliomas.
Kreiger PA; Okada Y; Simon S; Rorke LB; Louis DN; Golden JA
Acta Neuropathol; 2005 Apr; 109(4):387-92. PubMed ID: 15739101
[TBL] [Abstract][Full Text] [Related]
30. Identification of consistent novel submegabase deletions in low-grade oligodendrogliomas using array-based comparative genomic hybridization.
Rossi MR; Gaile D; Laduca J; Matsui S; Conroy J; McQuaid D; Chervinsky D; Eddy R; Chen HS; Barnett GH; Nowak NJ; Cowell JK
Genes Chromosomes Cancer; 2005 Sep; 44(1):85-96. PubMed ID: 15940691
[TBL] [Abstract][Full Text] [Related]
31. [The oligodendroglioma: the value of histologic and genetic diagnosis in predicting sensitivity to chemotherapy].
Kros JM
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1379-85. PubMed ID: 15997690
[TBL] [Abstract][Full Text] [Related]
32. [Towards a molecular classification of gliomas].
Hoang-Xuan K; Idbaih A; Mokhtari K; Sanson M
Bull Cancer; 2005 Apr; 92(4):310-6. PubMed ID: 15888387
[TBL] [Abstract][Full Text] [Related]
33. No preferential loss of paternal 19q alleles in oligodendroglial tumors.
Hartmann C; Mueller W; Lass U; Stockhammer F; von Eckardstein K; Veelken J; Jeuken J; Wick W; von Deimling A
Ann Neurol; 2003 Aug; 54(2):256-8. PubMed ID: 12891681
[TBL] [Abstract][Full Text] [Related]
34. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
35. Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas.
Yang P; Kollmeyer TM; Buckner K; Bamlet W; Ballman KV; Jenkins RB
Cancer; 2005 Jun; 103(11):2363-72. PubMed ID: 15834925
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine.
Stege EM; Kros JM; de Bruin HG; Enting RH; van Heuvel I; Looijenga LH; van der Rijt CD; Smitt PA; van den Bent MJ
Cancer; 2005 Feb; 103(4):802-9. PubMed ID: 15637687
[TBL] [Abstract][Full Text] [Related]
37. Detection of chromosomal changes by interphase cytogenetics in biopsies of recurrent astrocytomas and oligodendrogliomas.
Rosso SM; van Dekken H; Krishnadath KK; Alers JC; Kros JM
J Neuropathol Exp Neurol; 1997 Oct; 56(10):1125-31. PubMed ID: 9329456
[TBL] [Abstract][Full Text] [Related]
38. Survival analysis of presumptive prognostic markers among oligodendrogliomas.
McLendon RE; Herndon JE; West B; Reardon D; Wiltshire R; Rasheed BK; Quinn J; Friedman HS; Friedman AH; Bigner DD
Cancer; 2005 Oct; 104(8):1693-9. PubMed ID: 16116609
[TBL] [Abstract][Full Text] [Related]
39. Chromosome DNA imbalances in human astrocytic tumors: a comparative genomic hybridization study of 63 Chinese patients.
Jin S; Sun C; Yu S; Wang Q; Wu W; Sun Y; Zhao W; An T
Pathol Res Pract; 2010 Oct; 206(10):674-81. PubMed ID: 20591577
[TBL] [Abstract][Full Text] [Related]
40. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma.
Perry A; Aldape KD; George DH; Burger PC
Cancer; 2004 Nov; 101(10):2318-26. PubMed ID: 15470710
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
